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Background: Approximately 27% of Americans today are obese, and this condition increases 
the prevalence of metabolic syndrome and diabetes. The UK Prospective Diabetes Study 
suggests that loss of beta cell function can begin at least 10 years before diagnosis, and mean 
beta cell function is already less than 50% at diagnosis. The aim of this research was to assess 
the possibility of detecting loss of beta cell function in obese patients by a novel approach 
involving nitric oxide assessment using a combination of technologies.
Materials and methods: One hundred and fifteen obese patients (93 women, 22 men) of mean 
age 39 (range 17–62) years, who were candidates for bariatric surgery were included in the study, 
and underwent laboratory tests, including fasting blood glucose, fasting insulin plasma, and 
examination with the Electro Sensor complex. The Electro Sensor complex offers a new way to 
assess nitric oxide production using five technologies managed by software, ie, the galvanic skin 
response, photoelectrical plethysmography, heart rate variability analysis, bioimpedance analysis, 
and blood pressure oscillometric measurements. The homeostasis model assessment 2% beta 
cell function (HOMA2% β) algorithm was calculated from fasting blood glucose and fasting 
insulin plasma using free software provided by The University of Oxford Diabetes Trial Unit. 
The Electro Sensor complex percent beta (ESC% β) algorithm was calculated from the Electro 
Sensor complex data and statistical neural network. Statistical analysis was performed to cor-
relate ESC% β and HOMA2% β using the coefficient of correlation and Spearman’s coefficient 
of rank correlation. Receiver-operating characteristic curves were also constructed to determine 
the specificity and sensitivity of ESC% β in detecting a HOMA2% β value , 100.
Results: The coefficient of correlation between ESC% β and HOMA2% β was 0.72 (using log 
values) and the Spearman’s coefficient of rank correlation (rho) was 0.799 (P , 0.0001). ESC% 
β had a sensitivity of 77.14% and specificity of 78.21% (cutoff # 157, corresponding to 40% 
after conversion into a 0%–100% scale) to detect a HOMA2% β value , 100 (P , 0.0001).
Conclusion: The ESC% β algorithm has a high predictive correlation with HOMA2% β, and 
good specificity and sensitivity to detect a HOMA2% β value , 100. Therefore, the Electro 
Sensor complex enabling nitric oxide assessment represents a novel method of screening for beta 
cell function in the obese population on a large scale. Such a tool, which is easy to administer, 
noninvasive, and cost-effective, would be of great benefit for widespread screening of beta cell 
function in obese patients.
Keywords: beta cell function, Electro Sensor complex, nitric oxide assessment, ESC% 
β algorithm, HOMA2% β algorithm, obese population, screening
Introduction
During the past 20 years, the US has succumbed to a pervasive obesity epidemic.1,2 In 
1980, less than 47% of Americans were overweight (body mass index . 25 kg/m2) 
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and less than 15% were obese (body mass index . 30 kg/m2). 
Today, approximately 67% of Americans are overweight and 
over 27% are obese.2,3 Obesity increases the prevalence of 
the metabolic syndrome and diabetes.4,5 The pathogenesis of 
type 2 diabetes is hypothesized to be related to two principal 
factors, ie, insulin resistance and impaired glucose tolerance 
cell function.6 How do insulin resistance and beta cell dysfunc-
tion combine to cause type 2 diabetes?7 Over time, changes 
in insulin resistance and secretion lead to the onset of type 2 
diabetes. In the early stages, as insulin resistance rises, there 
is a compensatory increase in insulin secretion and glucose 
levels remain normal (normoglycemia). However, in the long 
term, as beta cell function begins to fail, insulin secretion 
decreases, impaired glucose tolerance and hyperglycemia 
become apparent, and frank type 2 diabetes develops.
Impaired glucose tolerance may be defined as higher 
than normal blood glucose levels, but not high enough to be 
called diabetes. People with impaired glucose tolerance may 
or may not go on to develop diabetes. Glucose levels before 
(fasting) and after (post-prandial) meals increase steadily as 
the individual progresses from normoglycemia to impaired 
glucose tolerance and, finally, to type 2 diabetes.
Extrapolation of the observed rate of decline in beta 
cell function in diet-treated subjects in the UK Prospective 
Diabetes Study suggests that loss of beta cell function can 
start at least 10 years before diagnosis of diabetesm, and 
that mean beta cell function may already be less than 50% at 
diagnosis.8,9 None of the therapies used in the UK Prospective 
Diabetes Study (sulfonylureas, metformin, and insulin) were 
able to prevent or delay the progressive deterioration of beta 
cell function.10 On average, beta cell function declines by 1% 
per year with normal aging, compared with 4% per year in 
diabetes.10,11 In view of these facts and the studies that have 
already established the correlation between obesity and 
insulin resistance, we undertook this study of screening for 
beta cell function in the obese population.
Beta cell function diagnostics are already available. The 
gold standard test includes the hyperinsulinemic-euglycemic 
clamp,11 and another accepted method is the minimal-model 
analysis frequently sampled intravenous glucose tolerance 
test.12 The oral glucose tolerance test is also accepted as a 
noninvasive minimal model for analysis.12 However, these 
tests are invasive, labor-intensive, and/or expensive, which 
discourages their use in large population-based epidemiologic 
studies. Sometimes used as a marker for beta cell dysfunc-
tion, the ratio of proinsulin (the precursor of insulin that is 
converted to insulin) to total insulin provides a measure of the 
efficiency of proinsulin processing.13 C-peptide is also used to 
assess beta cell function in type 1 diabetes when the insulin 
level is not interpretable due to insulin medication.14
The homeostasis model assessment percent beta 
(HOMA% β) algorithm is appropriate for large-scale screen-
ing, 15 and the new HOMA2% β algorithm improves the abil-
ity to assess beta cell function compared with the HOMA1% 
β algorithm.16 The HOMA2% β is an algorithm calculated 
from fasting blood glucose and plasma insulin, and correlates 
well with estimates using the euglycemic clamp method. It 
has been tested extensively against minimal-model analysis, 
and has been accepted for large-scale screening of beta cell 
function,17 with some restrictions, ie, in older patients.18
The Electro Sensor complex (LD Technology, Miami, FL) 
is a combination of five technologies managed by software, 
and the accuracy of some features, such as fat mass and cardiac 
output measurements, has been compared with recognized 
standardized assessment.19 The Electro Sensor complex fea-
tures include the galvanic skin response, heart rate variability 
analysis, photoelectrical plethysmography analysis, and blood 
pressure measurements. We consider that the Electro Sensor 
complex data are related to production of nitric oxide.
Electro Sensor complex data  
and nitric oxide
With regard to the galvanic skin response, electrical skin 
stimulation seems to be a mechanical shear stress which 
causes a phosphorylation cascade that removes phosphate 
groups from proteins and kinases, activating endothelial 
nitric oxide synthase to synthesize nitric oxide. Nitric oxide 
is produced, facilitating the release of cyclic guanosine 
monophosphate and a change in potassium permeability. 
Relaxation of smooth muscle and vasodilatation of vessels 
allows an exchange between the vessels and sweat glands, 
which facilitates the production of sweat.20,21
Photoelectrical plethysmography analysis provides a 
stiffness index, and blood pressure measurements are related 
to endothelial cell function which is related to nitric oxide 
  production.22 Fat mass is also related to nitric oxide.23 Finally, 
a study by Sartori et al found a significant relationship between 
nitric oxide production and heart rate variability analysis.24 
Zeng and Quon have performed a study showing the rela-
tionship between insulin production and nitric oxide using 
administration of wortmannin.25 The ESC% β algorithm can 
be calculated from Electro Sensor complex data. The aim of 
this research was to assess the possibility of detecting loss 
of beta cell function in obese patients using a novel approach 
of nitric oxide assessment using a combination of technologies 
comparing ESC% β and HOMA2% β.
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Materials and methods
Subjects
Obesity is associated with the metabolic syndrome and 
diabetes, and this study included obese patients who were 
candidates for bariatric surgery. Patients were excluded if they 
were on insulin or secretagogue treatment, had a neurological 
disorder precluding the ability to sign a consent form, were 
clinically unsuitable candidates for the trial in the opinion 
of the investigators, and/or had any contraindications to use 
of the Electro Sensor complex system. Use of the Electro 
Sensor complex system is contraindicated in the presence 
of an external defibrillator, skin lesions likely to come into 
contact with the electrodes, excessive perspiration, a cardiac 
pacemaker, electronic life support, any implanted electronic 
device, inability to remain still for three minutes, metallic pins 
or prostheses in digits or joints, and absence of a limb.
One hundred and fifteen obese patients (93 women, 
22 men) of mean age 39 (range 17–62) years were sent to 
the laboratory for fasting blood glucose and fasting insulin 
plasma tests. The patients underwent an Electro Sensor com-
plex measurement before these laboratory tests. The study 
was approved by the regional ethics committee, and adhered 
to the ethical principles of the Declaration of Helsinki. Each 
patient signed an informed consent form, and confidentiality 
was observed for all participants.
Laboratory tests
Fasting plasma glucose levels (mg/dL) were measured using 
the colorimetric enzymatic method. Fasting plasma insulin 
levels (µUI/mL) were determined using the chemolumi-
nescent immunoassay. Fasting for 8 hours was required for 
both tests. The HOMA2% β algorithm was calculated from 
fasting blood glucose and fasting insulin plasma. Glucose 
and insulin concentrations were converted to mmol/L and 
pmol/L, respectively. Calculations were performed using the 
free software provided by The University of Oxford Diabetes 
Trial Unit (http://www.dtu.ox.ac.uk/homacalculator). 
Because HOMA is a steady-state model, only clinical realistic 
values seen in a fasting subject were accepted for analysis 
(plasma glucose level 3.5–25 mmol/L and plasma insulin 
level 20–350 pmol/L).
Electro Sensor complex system  
and ESC% β algorithm
The Electro Sensor complex system is a novel method for 
assessing nitric oxide production using five technologies 
managed by software, ie, the galvanic skin response, photo-
electrical plethysmography, heart rate variability analysis, 
bioimpedance analysis, and blood pressure oscillometric 
measurements.
Nitric oxide assessment is expressed in the ESC% 
β algorithm, and calculated from the following data:
•	 Conductance of the foot-foot pathway, expressed in µSi 
(microSiemens), with a normal range of 8.33–14.71 µSi, 
from galvanic skin response technology
•	 Stiffness index, calculated from the height of the patient 
(in meters) divided by the time (seconds) between the 
two systolic peaks of the wave provided by the oximeter 
(photoelectrical plethysmography), expressed in m/sec, 
with a normal range of 7–9
•	 Standard deviation normal-to-normal represents the stan-
dard deviation of the entire recording of time between 
each heartbeat, expressed in msec, normal range 40–80, 
from heart rate variability domain analysis technology
•	 Fat mass percentage, expressed in kg, with a normal range 
according to age and gender, from bioimpedance analysis 
technology
•	 Systolic pressure, normal range , 140 mmHg, from the 
blood pressure device using oscillometric technology.
The ESC% β algorithm was performed using statistical 
neural network analysis software Statistica Version 7.26 Like 
the HOMA2% β algorithm, the ESC% β algorithm uses a 
calculator which is integrated into the Electro Sensor com-
plex software, and the results are expressed in percentage 
form. The scale of results is 0–100, and the normal range 
is 40%–60%.
Statistical analysis
Statistical analysis of the number of patients needed for 
the study was calculated using MedCalc software and was 
100 on the basis of α = 5%, at 80% power = F (∆, N, vari-
ability DS), taking into account the judgment criteria ∆ at 
approximately 100 DS (5% error). P , 0.005 was accepted 
as being statistically significant. The statistical analysis was 
performed to correlate the Electro Sensor complex data and 
HOMA2% β on the one hand, and to correlate ESC% β and 
HOMA2% β on the other, using the coefficient of correlation 
and the Spearman’s coefficient of rank correlation. Receiver-
operating characteristic curves were also constructed to 
determine the specificity and sensitivity of ESC% β to detect 
a HOMA2% β value , 100.
Results
Demographic data for the 115 patients included in the 
study are summarized in Table 1. The correlation between 
HOMA2% β and each parameter are summarized in Table 2. 
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Table 1 Demographic data for study participants
General demographic data
Women/men ratio 4.22
Age 38.7 ± 20
BMI 46.5 ± 14
Treatments Patients (n)
Metformin treatment 20
Antihypertensive agents 63
Parameters and units Values 
Foot conductance (µSi) 7.8 ± 4.3
SI (m/sec) 8.1 ± 1.16
SDNN (msec) 48.8 ± 12.9
Fat mass % total body weight 45 ± 11
Systolic pressure (mmhg) 134.1 ± 20.6
Algorithms Values
hOMA2% β 140 ± 73
ESC% β 222 ± 137.7
Note: Data are expressed as the mean ± standard deviation.
Abbreviations: BMI, body mass index; SI, stress index; SDNN, standard deviation 
normal-to-normal; hOMA2% β, homeostasis model assessment 2 percent beta cell 
function; ESC% β, Electro Sensor complex percent beta.
Table 2 Correlation between hOMA2% β and each parameter
Parameters r rho P
Foot conductance 0.56 0.65 0.01
SI 0.55 0.63 0.01
SDNN 0.64 0.70 0.001
Fat mass 0.44 0.49 0.03
Systolic pressure 0.53 0.62 0.01
Abbreviations: SI, stiffness index; SDNN, standard deviation normal-to-normal; 
r,  coefficient  of  correlation;  rho,  Spearman’s  coefficient  of  rank  correlation; 
hOMA2% β, homeostasis model assessment 2 percent beta cell function.
Table 3 Correlation between ESC% β algorithm and hOMA2% 
β algorithm
Correlation
Variable Y ESC
Variable X hOMA
Sample size 115
Correlation coefficient r 0.7216
Significance level P , 0.0001
95% confidence interval for r 0.6204–0.7991
Abbreviations: hOMA2% β, homeostasis model assessment 2 percent beta cell 
function; ESC% β, Electro Sensor complex percent beta.
Table 4 Spearman’s coefficient of rank coefficient between ESC% 
β and hOMA2% β
Rank correlation
Variable Y ESC
Variable X hOMA
Sample size 115
Spearman’s coefficient of rank correlation (rho) 0.799
Significance level P , 0.0001
95% confidence interval for rho 0.721–0.857
Abbreviations: hOMA2% β, homeostasis model assessment 2 percent beta cell 
function; ESC% β, Electro Sensor complex percent beta.
Correlation between the ESC% β and the HOMA2% β 
algorithms is summarized in Table 3. The coefficient of cor-
relation for ESC% β and HOMA2% β is r = 0.72 using log 
values (P , 0.0001). Spearman’s rank coefficient correlation 
between ESC% β and HOMA2% β is summarized in Table 4 
and in Figure 1. Spearman’s rank coefficient correlation (rho) 
was 0.799 (P , 0.0001). A receiver-operating characteris-
tic curve was constructed to determine the specificity and 
sensitivity of ESC% β to detect a HOMA2% β value , 100 
(Figure 2 and Table 5). ESC% β had a sensitivity of 77.14% 
and specificity of 78.21% (cutoff # 157 corresponding to 
40% after conversion using a scale of 0%–100%) to detect 
a HOMA2% β value , 100 (P , 0.0001).
Discussion
Mayaudon et al27 performed a study using a device which 
measured foot conductance to detect diabetes. In their study, 
foot conductance was reduced in diabetic patients compared 
with control subjects. However, this study compared a group of 
92 type 2 diabetic patients of mean age 58.9 ± 12.1 years, body 
mass index 28.3 ± 5.0, and mean diabetes duration 14 ± 10 
years, with about 50% having diabetic complications and 
on antidiabetic agents, including insulin and secretagogues, 
and a group of 41 healthy volunteers of mean age 25.5 ± 6.4 
years, none of whom were on treatment, and body mass index 
23.8 ± 2.7. Therefore, the results are biased in that the study 
compared two very different populations and it would be 
impossible to attribute the differences in foot conductance to 
age, complications, treatment, body mass index, or diabetes 
detection. Also, an algorithm including foot conductance, 
age, and body mass index was used, which has a sensitivity of 
75% and specificity of 100% to detect diabetes. With regard 
to the differences in age and body mass index between the 
two study groups, this algorithm result cannot be considered 
seriously. Ramachandran et al28 have also investigated the 
same device, the same parameters, and the same algorithm 
in a study from India using an equivalent population, and the 
specificity for detecting diabetes was more realistic and failed 
at 54%. Another study29 using only foot conductance showed 
this parameter to be useful for evaluating diabetic complica-
tions, such as foot neuropathy, but as a sole marker does not 
have enough specificity and sensitivity to detect diabetes.
Salomaa et al30 performed a cross-sectional study to assess 
the relationship between arterial stiffness, glucose tolerance, 
and serum insulin levels. All indices of arterial stiffness were 
higher when fasting glucose was above the normal level.31 
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Our study confirms this finding, and we found an acceptable 
correlation comparing HOMA2% β and stiffness index. 
Schroeder et al31 used heart rate variability analysis and the 
standard deviation normal-to-normal parameter to detect 
diabetes, and found a good correlation at P , 0.01. Our 
study confirms this finding. Ferrannini et al32 found that fat 
mass was highly correlated with insulin resistance, but the 
relationship between fat mass and beta cell function was not 
clear. Our study included only obese patients with body mass 
index . 40 kg/m2, and this parameter has a low correlation 
with HOMA2% β.
Finally, Davies et al33 compared systolic blood pressure 
and diabetes screening, and found the same correlation that we 
obtained in the present study. The ESC% β algorithm has a high 
predictive correlation with HOMA2% β, and good specificity 
and sensitivity to detect a HOMA2% β value , 100. The 
Electro Sensor complex which provides the ESC% β algorithm 
could be a new method of estimating beta cell function via nitric 
oxide assessment using a combination of technologies.
Electro Sensor complex-insulin resistance and Electro 
Sensor complex-blood glucose control algorithms using 
different Electro Sensor complex data and formulae have 
already been investigated and compared, respectively, with 
HOMA2-IR and glycosylated hemoglobin, with some success 
(Chaim EA, Gobato RC, Carvalho Ramos M, unpublished 
data, 2011). Furthermore, the Electro Sensor complex will be 
useful for early detection of diabetic complications, with regard 
to the role of nitric oxide in cardiovascular disease34 and renal 
oxygenation.35 New algorithms using Electro Sensor complex 
data will be investigated to detect cardiovascular risk and kidney 
risk. Finally, a longitudinal study is underway at the University 
of Miami using the Electro Sensor complex to detect diabetes 
not only in obese patients but also in the general population.
Conclusion
The ESC% β algorithm has a high predictive correlation 
with the HOMA2% β, and good specificity and sensitivity 
to detect a HOMA2% β value , 100, so the Electro Sensor 
complex system providing nitric oxide assessment would be 
a new method of screening for beta cell function in the obese 
population on a large scale. A tool which is easy to admin-
ister, noninvasive, and cost-effective would be of advantage 
and of great benefit for beta cell function screening.
Table 5 Receiver operating characteristic curve analysis: ESC% β 
versus hOMA2% β value , 100
Variable ESC% β
Classification variable DIAGNOSIS
Sample size 
Positive group: diagnosis 0 
Negative group: diagnosis 1
115 
35 
80
Disease prevalence (%) 31
Area under the ROC curve (AUC) 0.867
Standard errora 0.0334
95% confidence intervalb 0.790–0.924
z statistic 10.978
Significance level P (area = 0.5) ,0.0001
Notes: a Delong  et  al  1988  (http://www.medcalc.org/manual/comparison_of_
roc_curves.php); bbinomial exact (http://www.medcalc.org/manual/comparison_of_
roc_curves.php).
Abbreviations: hOMA2% β, homeostasis model assessment 2 percent beta cell 
function; ESC% β, Electro Sensor complex percent beta.
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Figure 1 Scatter diagram and regression line ESC% β and hOMA2% β.
Abbreviations: hOMA2% β, homeostasis model assessment 2 percent beta cell 
function; ESC% β, Electro Sensor complex percent beta.
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Figure  2  Receiver  operating  characteristic  curve  ESC%  β  versus  hOMA2% 
β value , 100.
Abbreviations: hOMA2% β, homeostasis model assessment 2 percent beta cell 
function; ESC% β, Electro Sensor complex percent beta.
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